直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Federal Circuit PTAB Appeal Statistics for May 2023

June 30, 2023

Authored and Edited by Daniel F. Klodowski; Audrey J. Parker; Jason E. Stach; Elliot C. Cook

In May, the Federal Circuit affirmed the PTAB on every issue in 12 (80%) cases on appeal from post-grant proceedings, including in three precedential opinions: Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc. (No. 21-1981), Bot M8 LLC v. Sony Interactive Entertainment LLC (No. 22-1291), and Medtronic, Inc. v. Teleflex Innovations S.A.R.L. (Nos. 21-2356, -2358, -2361, -2363, and -2365).  The Federal Circuit issued a mixed outcome in 1 (6.67%) appeal and reversed or vacated every issue in 2 (13.33%) appeals.  No appeals were dismissed, which may occur, for example, when the Federal Circuit determines that it does not have jurisdiction over an appeal. 

Through May 31, 2023, the Federal Circuit cumulatively decided 1,161 appeals from the PTAB in IPRs, CBMs, and PGRs.  While the vast majority of these appeals came from IPR proceedings, the number of PGR appeals has slowly increased over time.

In IPR appeals, the Federal Circuit has cumulatively affirmed the PTAB on every issue in 806 (73.74%) cases and reversed or vacated the PTAB on every issue in 140 (12.81%) cases.  A mixed outcome on appeal occurred in 113 (10.34%) cases, and the court dismissed 34 (3.11%) IPR appeals on non-settlement grounds without rendering a decision on the merits.   

In PGR appeals, the Federal Circuit cumulatively affirmed the PTAB on every issue in 12 (70.59%) cases, issued a mixed outcome in 1 (5.88%) case, and reversed or vacated every issue in 4 (23.53%) cases.  No PGR appeals have been dismissed on the merits.

Taken together, in decisions for IPR, CBM, and PGR appeals, the Federal Circuit affirmed every issue in 856 (73.73%) cases, issued a mixed outcome in 118 (10.16%) cases, reversed or vacated every issue in 149 (12.83%) cases, and dismissed 38 (3.27%) cases.

Of the 1,161 IPR, CBM, and PGR cumulative appeals that it has considered, the Federal Circuit issued Rule 36 affirmances in 502 (43.24%) cases.  The court issued written opinions, including affirmances, reversals, dismissals, and mixed decisions, in 659 (56.76%) cases.  The ratio of Rule 36 affirmances to issued decisions has trended steadily downward over time.

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

Related Offices

Atlanta, GA

Reston, VA

Washington, DC

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Jason E. Stach
Partner
Atlanta, GA
+1 404 653 6428
Email
Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email

Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Federal Circuit IP Blog

Federal Circuit Affirms § 102(b) Invalidity; Source Code Commands Are Not Hearsay

May 14, 2026

Federal Circuit IP Blog

When “and” and “e.g.” Matter: Federal Circuit Revives VLSI vs. Intel Case

May 14, 2026

IP Updates

Tenth Circuit Sides with Netflix in Tiger King Copyright Challenge 

May 5, 2026

Conference

International Trade Commission Litigation & Enforcement

May 4-5, 2026

Washington, DC

Articles

Unpacking Squires’ Recent Discretionary Denial Guidance Focusing on American Manufacturing

April 24, 2026

Federal Circuit IP Blog

Federal Circuit Affirms District Court’s Invalidation of Patents Because Inventorship Could Not Be Corrected Without Giving All Inventors Notice and an Opportunity to Be Heard

April 22, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP